TL;DR
Salt Lake City anchors a distinctive biotech cluster centered on computational biology and AI drug discovery - Recursion Pharmaceuticals, Myriad Genetics, BioFire Diagnostics, plus University of Utah spinouts. Insurance program shape differs from traditional biotech: heavier tech E&O for computational platforms, IP infringement defense for algorithmic IP, AI-specific D&O exposure on drug discovery warranties, and cyber for proprietary platform and genomic data flows. Premium typically runs comparable to mid-cluster biotech markets.
Salt Lake City biotech
Salt Lake City biotech insurance - Recursion, Myriad, BioFire, U of Utah spinouts.
Salt Lake City has become one of the leading US clusters for computational biology and AI-driven drug discovery. The cluster is anchored by Recursion Pharmaceuticals (AI drug discovery platform), Myriad Genetics (consumer and clinical genomics), and BioFire Diagnostics (PCR-based infectious disease diagnostics), plus a growing wave of University of Utah spinouts. The insurance underwriting picture reflects the cluster's technology-platform tilt: more tech E&O, more IP defense, more AI-specific exposure than traditional clinical-stage biotech.
Cluster characteristics
Platform technology dominates the insurance shape.
Recursion Pharmaceuticals represents the AI drug discovery archetype: insurance programs need tech E&O at elevated limits, IP infringement defense for algorithmic platform IP, and D&O architecture that anticipates AI-warranty exposure on partnered drug discovery programs.
Myriad Genetics and BioFire operate at commercial scale in genetic testing and infectious disease diagnostics respectively. Insurance demands include CLIA-regulated diagnostic exposure, products liability for test outputs, cyber under genomic and clinical data regulations, and patent infringement defense (Myriad in particular has been at the center of major patent litigation).
University of Utah spinouts follow standard clinical-stage architecture (D&O, clinical trial liability, IP/E&O for academic-IP) with attention to Utah-specific tech transfer office terms.
Utah regulatory overlay
UCPA, Utah Securities Division, lighter plaintiff posture.
Utah enacted the Utah Consumer Privacy Act (UCPA) effective December 2023, layering consumer-protection privacy obligations on top of HIPAA. Cyber liability programs should explicitly address UCPA defense for any consumer-facing genomic or health data flows.
Securities-class-action posture in District of Utah is lighter than coastal districts. D&O architecture can be sized somewhat tighter for SLC-headquartered post-IPO operators than for Bay Area or Boston equivalents.
Premium levels for SLC biotech track at parity with comparable Texas operators on most lines, with platform-technology specific lines (tech E&O, IP defense, AI-warranty D&O) priced individually based on platform maturity.
SLC biotech coverage review